Your browser doesn't support javascript.
loading
Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors.
Epstein, Robert S; Aapro, Matti S; Basu Roy, Upal K; Salimi, Tehseen; Krenitsky, JoAnn; Leone-Perkins, Megan L; Girman, Cynthia; Schlusser, Courtney; Crawford, Jeffrey.
Afiliación
  • Epstein RS; Epstein Health, LLC, Woodcliff Lake, NJ, USA. repstein@epsteinhealth.com.
  • Aapro MS; Clinique de Genolier, Genolier, Switzerland.
  • Basu Roy UK; LUNGevity Foundation, Bethesda, MD, USA.
  • Salimi T; G1 Therapeutics, Inc., Research Triangle Park, NC, USA.
  • Krenitsky J; Epstein Health, LLC, Woodcliff Lake, NJ, USA.
  • Leone-Perkins ML; HealthiVibe, Corrona, LLC, Arlington, VA, USA.
  • Girman C; CERobs Consulting, LLC, Chapel Hill, NC, USA.
  • Schlusser C; UNC Gillings School of Global Public Health, Chapel Hill, NC, USA.
  • Crawford J; UNC Gillings School of Global Public Health, Chapel Hill, NC, USA.
Adv Ther ; 37(8): 3606-3618, 2020 08.
Article en En | MEDLINE | ID: mdl-32642965
This study looked at people with cancer who received chemotherapy and developed a condition where their bone marrow activity was reduced, called myelosuppression. This meant they had fewer red blood cells that carry oxygen around the body, white blood cells that help fight infections, and platelets that help the blood to clot. The researchers wanted to understand how chemotherapy-induced myelosuppression affects peoples' lives and their cancer treatment, and people's experiences of treatment for myelosuppression. Overall, 301 people in the USA with breast, lung, or large bowel (colorectal) cancer completed an online survey. They had all received chemotherapy in the last year, and had myelosuppression at least once during their treatment. The survey showed that around 8 in 10 people (79%) had to be treated for myelosuppression, and around 7 in 10 people (73%) felt they received treatment for myelosuppression quickly. Chemotherapy was delayed, reduced, or stopped because of myelosuppression in around 6 in 10 people (64%). Around 3 in 10 people (30%) felt their oncologist did not understand the discomfort that myelosuppression caused them, and around 9 in 10 people (88%) felt that myelosuppression made their quality of life worse. The researchers concluded that because myelosuppression impacts peoples' lives and their ability to keep receiving chemotherapy to treat their cancer, effective prevention and treatment for this condition are important. Better communication between people and their health care teams could help them to understand how people experience myelosuppression and make plans for treatment together.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Neoplasias Colorrectales / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Neoplasias Pulmonares / Antineoplásicos Tipo de estudio: Prognostic_studies Aspecto: Patient_preference Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Adv Ther Asunto de la revista: TERAPEUTICA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Neoplasias Colorrectales / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Neoplasias Pulmonares / Antineoplásicos Tipo de estudio: Prognostic_studies Aspecto: Patient_preference Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Adv Ther Asunto de la revista: TERAPEUTICA Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos